Regulatory Requirements for the Quality of Allergen Products for Allergen Immunotherapy of Food Allergy.


Journal

Current allergy and asthma reports
ISSN: 1534-6315
Titre abrégé: Curr Allergy Asthma Rep
Pays: United States
ID NLM: 101096440

Informations de publication

Date de publication:
10 05 2021
Historique:
accepted: 15 09 2020
entrez: 10 5 2021
pubmed: 11 5 2021
medline: 16 10 2021
Statut: epublish

Résumé

Medicinal products for allergen immunotherapy (AIT) of food allergies have gained enormous momentum in recent years. With this new class of products entering marketing authorization procedures, compliance to regulatory requirements becomes a critical element. Here, an overview is provided on specific requirements and aspects concerning the quality control and manufacturing of these products. Recent developments in the field of AIT for food allergies are divers, including products for oral, epicutaneous, and subcutaneous application, most notably targeting egg, milk, and peanut allergy. As the source materials for food AIT product are typically produced for food consumption and not for medicinal purposes, unique challenges arise in the manufacturing processes and controls of these medicinal products. Individual approaches are needed to assure acceptable quality, including control of relevant quantitative and qualitative characteristics. Major characteristics for quality verification include determination of protein content, total allergenic activity, and major allergen content. The applied manufacturing processes need to be established such that relevant process parameters are kept within justified limits and consistency of produced batches is assured. Allergen products for food AIT present specific challenges with respect to quality aspects that differentiate them from other commonly available AIT products. While established regulation is available and provides clear guidance for most aspects, other issues require consideration of new and individual settings relevant here. Consequently, as experience grows, respective amendments to currently available guidance may be needed.

Identifiants

pubmed: 33970347
doi: 10.1007/s11882-021-01008-9
pii: 10.1007/s11882-021-01008-9
pmc: PMC8110504
doi:

Substances chimiques

Allergens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

32

Références

Int Arch Allergy Immunol. 2015;166(1):41-51
pubmed: 25765512
JAMA. 2019 Mar 12;321(10):946-955
pubmed: 30794314
Br J Nutr. 2006 Nov;96 Suppl 2:S95-102
pubmed: 17125539
J Allergy Clin Immunol. 2015 May;135(5):1240-8.e1-3
pubmed: 25656999
Ann Allergy Asthma Immunol. 2017 Mar;118(3):356-364.e3
pubmed: 28087382
Allergy Asthma Proc. 2019 Jul 23;40(4):214-220
pubmed: 31122310
Curr Allergy Asthma Rep. 2019 Nov 25;19(11):53
pubmed: 31768649
J Allergy Clin Immunol. 2017 Apr;139(4):1242-1252.e9
pubmed: 28091362
J Investig Allergol Clin Immunol. 2017;27(3):151-159
pubmed: 28102823
Mol Nutr Food Res. 2009 Aug;53(8):963-9
pubmed: 19603402
Food Chem. 2017 Apr 15;221:335-344
pubmed: 27979211
J Allergy Clin Immunol. 2019 Nov;144(5):1320-1326.e1
pubmed: 31493887
Allergy. 2020 Jun;75(6):1337-1346
pubmed: 32034781
N Engl J Med. 2018 Nov 22;379(21):1991-2001
pubmed: 30449234
Nutrients. 2018 Sep 11;10(9):
pubmed: 30208580
Allergol Immunopathol (Madr). 1989 Mar-Apr;17(2):53-65
pubmed: 2672743
Allergy. 2018 Apr;73(4):799-815
pubmed: 29205393
J Allergy Clin Immunol. 2012 Dec;130(6):1260-74
pubmed: 23195525
Ann Allergy Asthma Immunol. 2017 Aug;119(2):101-107
pubmed: 28801015
J Allergy Clin Immunol Pract. 2020 Jan;8(1):368-370
pubmed: 31520844
Pediatr Allergy Immunol. 2018 Jun;29(4):341-349
pubmed: 29369411
Ann Allergy Asthma Immunol. 2018 Aug;121(2):145-149
pubmed: 29909055
J Allergy Clin Immunol. 2000 Oct;106(4):763-8
pubmed: 11031348
Allergy. 2019 May;74(5):986-995
pubmed: 30506686
Allergy. 2018 Jan;73(1):64-76
pubmed: 28771830

Auteurs

Lisa Englert (L)

Paul-Ehrlich-Institut, Langen, Germany.

Vera Mahler (V)

Paul-Ehrlich-Institut, Langen, Germany.

Andreas Bonertz (A)

Paul-Ehrlich-Institut, Langen, Germany. andreas.bonertz@pei.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH